sarilumab
Reading File
Finding Sources
Reading File
Reading File
Reading File
Here is a comprehensive overview of sarilumab:
Sarilumab (Brand name: KEVZARA)
Class & Mechanism
Sarilumab is a recombinant monoclonal antibody (biologic DMARD / bdMARD) that acts as an IL-6 receptor antagonist. It binds to both soluble and membrane-bound IL-6 receptors, blocking signaling by IL-6 — a key proinflammatory cytokine central to the pathogenesis of rheumatoid arthritis (RA). — Katzung's Basic and Clinical Pharmacology, 16th Ed.
Pharmacokinetics
- Half-life: 8–10 days (concentration-dependent)
- Bioavailability: ~80%
- Route: subcutaneous injection every 2 weeks
- Katzung's
Indications
- Rheumatoid arthritis (moderate to severe) — as monotherapy or combined with methotrexate or other conventional synthetic DMARDs (csDMARDs)
- Sarilumab monotherapy has shown superiority over adalimumab monotherapy in RA
- Investigated in polymyalgia rheumatica — a trial showed sarilumab 200 mg SC q2 weeks + 14-week glucocorticoid taper produced higher rates of sustained remission vs. glucocorticoids alone — Harrison's Principles of Internal Medicine, 22nd Ed.
Dosage
- 200 mg subcutaneously every 2 weeks
Adverse Effects
| Effect | Details |
|---|---|
| Infection | Most common adverse effect |
| Neutropenia, thrombocytopenia, anemia | Monitor CBC |
| Transaminitis | >1.5× ULN possible; monitor LFTs |
| Hyperlipidemia | Elevated triglycerides and LDL; monitor and treat if abnormal |
| GI perforation | Reported in association with diverticulitis |
| Injection site reactions | Similar to other SC biologics |
Katzung's; Lippincott Illustrated Reviews: Pharmacology
Comparison with Tocilizumab
Both sarilumab and tocilizumab are IL-6 receptor inhibitors used in RA. The key differences:
- Tocilizumab can be given IV (every 4 weeks) or SC (every 2 weeks); sarilumab is SC only (every 2 weeks)
- Adverse effect profiles are similar (elevated LFTs, hyperlipidemia, neutropenia, hypertension, injection/infusion site reactions)
- Lippincott Illustrated Reviews: Pharmacology
Context in RA Management
Sarilumab belongs to the biologic DMARD (bDMARD) class used after inadequate response to conventional DMARDs (e.g., methotrexate). Other agents in the RA armamentarium include TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab, golimumab), abatacept, rituximab, and JAK inhibitors (tofacitinib, baricitinib, upadacitinib). — Lippincott Illustrated Reviews: Pharmacology
Summary: Sarilumab is an IL-6 receptor blocker used primarily for moderate-to-severe RA, administered as a 200 mg subcutaneous injection every 2 weeks. Its main risks are infection, cytopenias, liver enzyme elevation, and dyslipidemia — all requiring routine monitoring.
This is a shared conversation. Sign in to Orris to start your own chat.